RxDoctor Payments Data

Joanna Chon, MD

Urogynecology and Reconstructive Pelvic Surgery · Naples, FLNPI 1477602068

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,214 of the $9,148 with a category attached, or 78.9%. 43 manufacturers reported payments, led by Axonics, Inc. at 25.5% of the total. 2025 is the largest year on record at $3,872, 7.9 times the $490 reported in 2019.

$9,148in general payments, 2019–2025

Across 274 payments — averaging $33.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$987
  • Medtronic$636
  • Johnson & Johnson$509
  • Coloplast$449
  • Boston Scientific$404
  • plus $4K from 37 others

What the payments were for

  • Travel & lodging$1,49016%
  • Food & beverage$7,21479%
  • Education$4445%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,148 in reported general payments places this provider in the 65th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

See all urogynecology and reconstructive pelvic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$446,107
Medicare patients
834
Services billed
18,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron250$213,417
GemtesaVibegron154$154,173
Estradiol511$28,005
Solifenacin Succinate573$20,876
Methenamine Hippurate143$9,728
Mirabegron ErMirabegron11$6,852
Tolterodine Tartrate ErTolterodine Tartrate101$6,834
Fesoterodine Fumarate ErFesoterodine Fumarate68$5,902
Darifenacin ErDarifenacin Hydrobromide12$4,542
Trospium Chloride ErTrospium Chloride37$4,408
Oxybutynin Chloride ErOxybutynin Chloride82$2,573
Tamsulosin Hcl195$2,496
Cefixime30$1,700
Cephalexin260$1,353
Desmopressin Acetate34$1,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$987$213,417250 claims
Sumitomo Pharma America, Inc.Gemtesa$137$154,173154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.

Other urogynecology and reconstructive pelvic surgery in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →